Short review

SARS-CoV-2 variants – Evolution, spike protein, and vaccines

Kai-Wei K. Chen a,1, Daniel Tsung-Ning Huang a,b,1, Li-Min Huang c,*

a Department of Pediatrics, MacKay Children’s Hospital, Taipei, Taiwan
b Department of Medicine, MacKay Medical College, Taipei, Taiwan
c Department of Pediatrics, National Taiwan University Children’s Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

Abstract

Despite the rising natural and vaccines mediated immunity, several countries have experienced a resurgence of the Coronavirus disease of 2019 (COVID-19) due to the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. From Alpha to Omicron, the variants of concern (VOC) have evolved several spike protein mutations that may have an impact on virus characteristics, such as transmissibility and antigenicity. In this review, we describe the evolution of SARS-CoV-2, summarize current knowledge of epidemiological and clinical features of the variants, and discuss the response strategies in terms of vaccines to reduce the burden of COVID-19.
SARS-CoV-2 evolves slowly with a rate of $1 \times 10^{-3}$ substitutions/site/year (or around 2 substitutions per genome per month) [2,3] due to the proof-reading function of an exonuclease enzyme encoded by nonstructural gene nsp14 [4]. This rate is slower than that of most RNA viruses. Nonetheless, selective evolutionary pressure was evident with the detection of a viral variant containing spike mutation D614G. This particular variant was initially found in early 2020; it then spread globally, out-competed previous viruses, and became the dominant form with a prevalence of almost 100% by June 2020 [5].

Following the emergence of D614G substitution, several novel lineages with mutations occurring primarily, but not exclusively, in spike proteins have been reported [Table 1]. Most of these mutations are convergent, meaning they occur independently in different lineages, possibly due to a response to the changing immune profile or chronic infections in individuals who are immunocompromised [6,7] or individuals receiving partially effective interventions [8]. In December 2020, the B.1.1.7 variant, presenting with numerous genetic changes, emerged in the United Kingdom (UK) [9]. Almost concurrently, two other variants, B.1.351 and P.1 emerged independently and caused a surge of new cases in South Africa [10] and Brazil [11], respectively. In January 2021, Manaus, Brazil, experienced a resurgence of COVID-19 due to the emergence of variant P.1 despite its high seroprevalence from the first epidemic wave [12]. Similarly, in April 2021, with the seroprevalence around 50% after enduring three waves of the SARS-CoV-2 pandemic, India encountered the fourth wave caused by the B.1.617.2 variant [13]; this variant then spread globally and displaced other variants in multiple countries [14–16]. At the beginning of November 2021, a highly divergent variant B.1.1.529 with a high number of mutations was detected in Botswana, South Africa [17]. Since then, South Africa has experienced a surge of cases, increasing from 280 to 800 cases per day; spreading rapidly and displacing B.1.617.2, B.1.1.529 has become the dominant variant in South Africa [18].

SARS-CoV-2 variants that have expanded widely and displayed the potential to be associated with increased transmissibility, disease severity, or change in interactions with host immunity are classified as variant of concern (VOC) by the WHO. Variants that display similar mutations as VOC but spread less widely are classified as variant of interest (VOI). As of April 1, 2022, there are five VOI classified by WHO and are designated as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529). Although most mutations observed are expected to be either neutral or mildly deleterious, the spike protein mutations that may alter the antigenicity of the SARS-CoV-2 are of particular importance. Nevertheless, whether these mutations will alter the variants’ pathogenicity, infectivity or antigenicity remains to be determined.

### Spike protein: structure, mutations, and antigenicity

The ability of VOI to escape neutralization by antibodies elicited by infection, vaccination, or therapeutic application has been widely studied [19–21]. It is essential to know the structure and function of the spike protein in order to understand how mutations in the SARS-CoV-2 spike protein affect neutralization. The transmembrane spike glycoprotein is responsible for SARS-CoV-2 entry into the host cell. The spike protein is cleaved by furin into two subunits, S1 and S2. A part of the S1 subunit, named receptor-binding domain (RBD), can bind to the human angiotensin-converting enzyme 2 (ACE2) receptor and thus begin the process of entering cells. A part of RBD called receptor-binding motif (RBM) forms direct contact with the ACE2 receptor. Spike RBD is also the main target of neutralizing antibodies upon infection and is the key to a vaccine or other therapeutic development [22]. Similar to RBD, the S1 amino-terminal domain (NTD) is also exposed on the protein surface, and evidence shows that NTD plays a substantial role in antigenicity as well [23]. Most monoclonal antibodies (mAbs) bind to RBD, while others target the NTD. Furthermore, some neutralizing Abs may also bind to the S1 carboxy-domain or S2 subunit, but RBD-targeting and NTD-targeting Abs may be much more potent [24].

Several mutations in components of the spike protein may significantly affect the neutralizing activity of mAbs, thus enabling VOC and VOI to escape immunity and spread in a population with rising immunity. E484 is an important residue on RBD that can be recognized by polyclonal antibodies in convalescent sera. It has been demonstrated that amino acid substitution to K, Q or P can significantly reduce neutralization titers [25]. E484K, which is the substitution of amino acid

### Table 1 Key mutations and proposed effects in different variants of concern.

| Mutations and proposed effects | Alpha (B.1.1.7) | Beta (B.1.351) | Gamma (P.1) | Delta (B.1.617.2) | Omicron BA.1 | Omicron BA.2 | Omicron BA.4 | Omicron BA.5 | Omicron BA.2.12.1 |
|--------------------------------|----------------|---------------|-------------|------------------|--------------|--------------|--------------|--------------|-----------------|
| D614, increase transmission   | G              | G             | G           | G                | G            | G            | G            | G            | G               |
| Δ69–70, increase transmission | Deletion       | K             | K           | Deletion         | A            | A            | A            | A            | A               |
| E484, K and Q decrease        |                |               |             |                  |              |              |              |              |                  |
| neutralization                |                |               |             |                  |              |              |              |              |                  |
| K417, decrease neutralization | N              | T             | N           | N                | N            | N            | N            | N            | N               |
| L452, decrease neutralization | R              |               | R           |                  | R            | R            | R            | R            | Q               |
| N501, increase transmission   | Y              | Y             | Y           | Y                | Y            | Y            | Y            | Y            | Y               |
| P681, increase transmission   | H              | R             | H           | H                | H            | H            | H            | H            | H               |
glutamic acid (E) with lysine (K) at position 484 of RBD, is an escape mutation that has been found in the Beta and Gamma VOCs and some of the VOIs. It facilitates escape from antibodies in convalescent plasma [25–27] and several mAbs such as casirivimab and bamlanivimab [28,29]. In addition, E484K has also been shown to escape from plasma samples collected from people vaccinated with mRNA vaccines [29]. Other RBD escape mutations include K417 N/T and L452R. K417N/T is found in the Delta, Gamma, and Omicron VOCs. They are related to escape from mAb such as etesevimab [30,31] but remain susceptible to convalescent plasma and plasma from persons vaccinated with BNT162b2 or mRNA-1273 [32]. L452R is present in Delta, Omicron subvariants BA.4 and BA.5, and it has been shown to reduce neutralizing activity by several mAbs [28,33] and convalescent plasma [33].

Several other mutations also contribute to the antigenicity of VOCs. For example, N501Y is another RBD mutation found in the Alpha, Beta, Gamma, and Omicron VOCs. It has been shown to increase ACE2 receptor affinity [30], but its antigenic impact is limited to a few monoclonal Abs. Furthermore, it is rarely associated with the reduced neutralizing activity of convalescent plasma or vaccine sera [32]. P681H/R is a mutation occurring close to the S1/S2 furin cleavage site. It has been shown to increase SARS-CoV-2 virulence by increasing S1/S2 cleavage [34]. P681H is reported in Alpha and Omicron VOCs, while P681R is found in the Delta VOC.

One of the NTD mutations, deletion at the position 69–70, has been shown to be associated with increased viral replication [35]. It is also used as a proxy to monitor certain VOCs [36]. One widely used PCR method for diagnosing SARS-CoV-2 amplifies three target genes. When one of the gene targets is missing (69/70 deletion), the spike gene target cannot be amplified on a specific PCR assay, and this creates a reproducible phenomenon called S gene target failure (SGTF). SGTFs have been seen in the Alpha and Omicron VOCs [18].

**Alpha variant (B.1.1.7)**

The Alpha VOC has multiple mutations in RBD, most notably N501Y, P681H, and 69/70 deletion. SGTF has been used as a proxy to monitor this variant. It first emerged in the UK in September 2020 and had been detected in several other countries, including the USA, by early 2021 [37]. Data suggest that the Alpha VOC is 43–90% more transmissible than other pre-existing lineages circulating in the UK [36,38,39]. In terms of disease severity, although some reports demonstrated no clear evidence between the Alpha VOC and increased mortality [39,40], others have shown its association with more severe diseases [41–43]. Nevertheless, the Alpha variant is susceptible to most mAbs and convalescent and vaccine (mRNA-1273 and BNT162b2) sera [32,44,45]; however, its impact on antibody response in AZD1222 has been inconsistent [46,47].

**Beta variant (B.1.351)**

The Beta VOC has three RBD mutations (N501Y, E484K, and K417N) and some NTD mutations except 69/70 deletion. It was first identified in South Africa in October 2020, and cases have been found outside South Africa ever since. There is no clear evidence suggesting an association of this variant with increased mortality, but some reports have shown that E484K mutation may affect neutralization by several mAbs, including casirivimab, bamlanivimab, and etesevimab [28,32,48]. Furthermore, the Beta variant is more resistant to neutralizing activity by convalescent plasma [48] and sera from individuals immunized with mRNA-1273, BNT162b2 [32], and AZD1222 [49].

**Gamma variant (P.1)**

RBD mutations N501Y, E484K, and K417N were identified in the Gamma VOC. This variant caused a surge of infection in Manaus, where a majority of the population had already been infected with SARS-CoV-2, and it is associated with increased transmissibility, risks of reinfection, and mortality [11,12,50]. Similar to the Beta VOC, the Gamma variant is refractory to neutralizing the activity of several mAbs, convalescent plasma, and vaccine sera [48,51,52].

**Delta variant (B.1.617.2)**

The Delta VOC was first detected in India in early 2021. This variant contains RBD mutation L452R and furin cleavage site mutation P681. In addition, it has several other spike protein mutations (T19R, R158G, T478K, and D950N) and mutations within orf3, orf7a, and nucleocapsid genes [53]. Rapidly displacing the Alpha variant in multiple countries [14] and becoming the dominant global VOC, the Delta variant has shown increased transmissibility because of the following possible mechanisms: higher infectious viral load [54], longer duration of shedding infectious virus [55], and a higher rate of reinfection due to antibody escape [56]. The susceptibility of the Delta VOC to convalescent plasma and sera from recipients of BNT162b2 and AZD1222 is reduced [47,56,57], but one study showed that BNT162b2 offered more protection from the Delta variant than AZD1222 did [58]. Also, the Delta VOC may be resistant to bamlanivimab and some other mAbs [47].

**Omicron variant (B.1.1.529)**

On November 26, 2021, Omicron was first identified in Bostwana, South Africa. Within three weeks, new cases have also been detected in more than 50 countries worldwide [59]. This variant was later divided into six subvariants namely BA.1, BA.2, BA.3, BA.4, BA.5, and BA.2.12.1, and they are genetically and antigenically different from each other [60]. Due to increased transmissibility, BA.1 displaced Delta and become the globally dominant SARS-CoV-2 strain [61]. BA.2 later replaced BA.1 rapidly in several countries [59,62]. Nevertheless, new Omicron subvariants continue to emerge; BA.4/5 and BA.2.12.1 had become the dominant strain in South Africa and the United States [63–65], and they all present higher transmission advantage over BA.2 [66]. Omicron contains more than 30 mutations in its spike proteins; some of these mutations, particularly those involving
RBD and NTD, are predicted to influence antibody neutralization epitopes. Omicron subvariants share several common mutations, yet they also have many unique mutations of their own [67]. Shared mutations such as E484, K417N, T478K, N501Y, and P681H are found in other VOCs, and they are reported to be associated with increased transmissibility, higher ACE2 binding affinity, and higher antibody escape [59]. In addition to these common spike mutations, BA.1 carries 13 more unique amino-acid mutations while BA.2 carries 8 more mutations [68]. BA.4, BA.5, and BA.2.12.1 display same RBD sequences to BA.2; in addition, BA.4 and BA.5 contain L452R and F486V mutations while BA.2.12.1 has L452Q substitution [66]. Notably, similar to the Alpha variant, BA.1, BA.4, and BA.5 can be detected by SGTF due to 69/70 deletion, but BA.2 and BA.2.12.1 lack 69/70 deletion.

Several studies have shown reduced neutralizing activity of vaccine serum against Omicron BA.1. These vaccines include two doses of the ChAdOx1-S vaccine [69,70], two doses of the mRNA vaccine (mRNA-1273 and BNT162b2 [69–71]), and heterologous vaccination with the ChAdOx1-S and BNT162b2 vaccines [69]. Convalescent serum from persons who had been infected with the Alpha, Beta or Delta VOC also showed low neutralizing activities against BA.1 [69,72]. However, the serum samples collected from individuals infected with SARS-CoV-2 and then vaccinated [69,72] and individuals vaccinated with boosters (third dose with mRNA vaccines) [61,70–72] showed detectable neutralizing antibodies against BA.1. The neutralizing activities of vaccine serum against BA.1 and BA.2 are similar [68,73], and the vaccine effectiveness of booster doses against symptomatic disease and hospitalization is also similar for BA.1 and BA.2 [74]. However, one study found that comparing to BA.1, BA.2 was associated with increased susceptibility of infection for unvaccinated, fully vaccinated and booster-vaccinated individuals [75]. BA.4/5 and BA.2.12.1, on the other hand, exhibit more neutralization evasion than BA.2 against the plasma from 3 doses of BNT162b2 [65] and Coronavirus [66].

Cross-reactivities between different VOCs and Omicron subvariants have been investigated. One study revealed that unvaccinated individuals who had no previous SARS-CoV-2 infections before infection with BA.1 developed neutralizing antibodies against BA.1 mostly, and no significant neutralizing activity against other VOCs was found [76]. Moreover, although one study showed a certain degree of cross-reactivity between BA.1 and BA.2 [68], others found poor cross-reactivity of BA.1/2-specific neutralizing Abs against BA.4/5 and BA.2.12.1 [66,77].

Several therapeutic mAbs, including bamlanivimab, imdevimab, casirivimab, and etesevimab, were evaded by BA.1, BA.2, BA.4/5 and BA.2.12.1 [78]. Sotrovimab, however, was able to maintain its function at a reduced efficacy against BA.2 as compared to Delta or D614G virus [64,78–80]. Although sotrovimab was less effective against BA.2 than the parental virus, BA.4/5 BA.2.12.1 were more sensitive to sotrovimab than BA.2 [76]. Few other mAbs, such as bixavirab/ligavirab and adintrevimab, were partly active against BA.2 and BA.4/5 [64,65,78,80].

Response strategies to emerging variants

Different SARS-CoV-2 variants have emerged independently around the globe against the background of increasing population immunity. Various strategies have been used to reduce the burden of VOCs and VOIs, and most of the strategies remain effective. For instance, no report shows that existing public health prevention measures, such as wearing masks, social distancing, and hand hygiene, are ineffective against various variants. Moreover, several therapeutic mAbs (e.g. sotrovimab) and antiviral agents (e.g. remdesivir and molnupiravir) remain active against most VOCs and VOIs [21,81]. The protection provided by the vaccines, however, may be the principal concern.

Several countries are experiencing the resurgence of COVID-19 due to emerging VOCs and waning vaccine-induced immunity. Studies indicate a progressive waning of immunity provided by previous doses of COVID-19 vaccines [82,83], and some emerging variants are less susceptible to neutralizing activity of these vaccines [84,85]. It is inferred that in response to waning immunity and the rise of new variants such as Omicron, vaccine boosters should be considered because they can increase immunogenicity after the initial course of vaccines. Affinity maturation of antibodies may be the underlying mechanism of the improved humoral response against SARS-CoV-2 [85]. Furthermore, several studies have shown that administering a booster dose using currently licensed mRNA vaccines can offer protection against symptomatic infection, hospitalization or mortality associated with emerging VOCs [74,87–89]. Although a heterologous prime-boost schedule can be more immunogenic and reactogenic than a homologous prime-boost schedule [90,91], policymakers should still consider administering a booster dose to reduce severe COVID-19-related outcomes.

Introducing modified and new vaccines with antigens that are effective against pre-existing variants is another possible solution to enhance protection against emerging VOCs that may become vaccine-resistant [92]. One study indicated that using an mRNA vaccine integrated with spike mutations from the Beta variant as a booster can increase both wild-type and Beta variant neutralization titers in mice [93]. However, more studies are required to determine whether new immunogens can elicit a wider and longer-lasting response to VOCs rather than boosting existing antibodies generated by previous infections or current vaccinations. Until then, genomic surveillance with continued sharing of data, public health prevention measures, and full vaccination with boosters may be the best strategies to alleviate the impact of emerging variants.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Conflicts of interest

We have no conflicts of interest to disclose.

Acknowledgement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

REFERENCES

[1] Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020;91:157–60.
[2] Candido DS, Claro IM, De Jesus JG, Souza WM, Moreira FRR, Dellicour S, et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil. Science 2020;369:1255–60.
[3] Peresos MJ, M relentless, Garcia GH, Di Lello FA. Phylogenetic analysis of SARS-CoV-2 in the first few months since its emergence. J Med Virol 2021;93:1722–31.
[4] Minskaia E, Hertzig T, Gorbalenya AE, Campanacci V, Camillau C, Canard B, et al. Discovery of an RNA virus 3’ → 5’ exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc Natl Acad Sci USA 2006;103:5108–13.
[5] Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 2020;182:812–27. e19.
[6] Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med 2020;383:2291–3.
[7] Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell 2020;183:1901–1912.e9.
[8] Kemp SA, Collier DA, Darji RF, Ferreira IATM, Gayed S, Jahn A, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature 2021;592:277–82.
[9] Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Genom Epidemiol 2020 Dec;1:5.
[10] Talgamy H, Wilkinson E, Althaus CL, Giovanetti M, San JE, Giandhari J, et al. Rapid replacement of the Beta variant by the Delta variant in South Africa. medRxiv 2021.09.23.21264018 [Preprint]. 2021 [cited 2022 June 20]. Available from: https://www.medrxiv.org/content/10.1101/2021.09.23.21264018v1.
[11] Bolze A, Luo S, White S, Cirulli ET, Wyman D, Dei Rossi A, et al. SARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loads. Cell Reports Medicine 2022;3:100564.
[12] World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern, https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern; 2021 [accessed 26 November 2021].
[13] National Institute for Communicable Diseases. Tracking SARS-CoV-2 Variants, https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/sars-cov-2-genomic-surveillance-update/; 2021 [accessed 14 December 2021].
[14] Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 2021;19:409–24.
[15] Lazarevic I, Pravica V, Miljanovic D, Cupic M. Immune evasion of SARS-CoV-2 emerging variants: what have we learnt so far? Viruses 2021;13:1192.
[16] Tao K, Tsou PL, Nounin J, Gupta RK, de Oliveira T, Kosakovski Pond SL, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet 2021;22:757–73.
[17] Piccoli I, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 2020;183:1024–42. e21.
[18] Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, Zost SJ, et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell 2021;184:2316–31. e15.
[19] Poh CM, Carissimo G, Wang B, Amrun SN, Lee CYP, Chee RS, et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nat Commun 2020;11:2806.
[20] Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 2021;29:463–76. e6.
[21] McCarthy KR, Rennick LJ, Nambulli S, Robinson-McCarty LR, Bain WG, Haidar G, et al. Recurrent deletions in the SARS-CoV-2 spike protein variants. Elife 2020;9:e61312.
[22] Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Liu X, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 2021;29:477–88. e4.
[23] Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 2020;369:1139–42.
[24] McInnes CB, Addetia A, Melanets A, Barvian KS, De Meyer AS, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife 2020;9:e61312.
[25] Yang J, Liu X, Liu Z, Zou L, Yang L, Liu S, et al. Neutralizing activity of polyclonal human plasma antibodies against SARS-CoV-2 variants. Sci Rep 2021;11:20152.
[26] Carabelli A, et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Genom Epidemiol 2020 Dec;1:5.
[27] Tegally H, Wilkinson E, Althaus CL, Giovanetti M, San JE, Giandhari J, et al. Rapid replacement of the Beta variant by the Delta variant in South Africa. medRxiv 2021.09.23.21264018 [Preprint]. 2021 [cited 2022 June 20]. Available from: https://www.medrxiv.org/content/10.1101/2021.09.23.21264018v1.
viral mutations that escape antibodies used to treat COVID-19. Science 2021;371:850–4.

[32] Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7. Nature 2021;593:130–5.

[33] Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 2020;182:1284–94. e9.

[34] Johnson BA, Xie X, Bailey AI, Kalveram B, Lokugamage KG, Muruato A, et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature 2021;591:293–9.

[35] Meng B, Kemp SA, Papa G, Datir R, Ferreira IATM, Marelisi S, et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7. Cell Rep 2021;35:109292.

[36] Voze E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England. Nature 2021;593:266–9.

[37] Centers for Disease Control and Prevention. Science Brief: Emerging SARS-CoV-2 Variants, https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html; 2021 [accessed 15 December 2021].

[38] Lyngse FP, Mølbak K, Skov RL, Christiansen LE, Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Breugem TI, et al. Omicron BA. 1 and BA. 2 are antigenically distinct SARS-CoV-2 variants. bioRxiv 2022.02.23.481644 [Preprint]. 2022 [accessed 15 June 2022].

[39] Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant. N Engl J Med 2021;384:1885–98.

[40] Freitas AR, Lemos DR, Beckedorff OA, Cavalcante LP, Siqueira AM, Mello RC, et al. The increase in the risk of severity and fatality rate of covid-19 in southern Brazil after the emergence of the Variant of Concern (VOC) SARS-CoV-2 P. 1 was greater among young adults without pre-existing risk conditions. medRxiv 2021.04.13.21255281 [Preprint]. 2021 [cited 2022 June 20]. Available from: https://www.medrxiv.org/content/10.1101/2021.04.13.21255281v1.

[41] Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G, et al. Increased resistance of SARS-CoV-2 variant P. 1 to antibody neutralization. Cell Host Microbe 2021;29:747–51. e4.

[42] Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Antibody evasion by the P. 1 strain of SARS-CoV-2. Cell 2021;184:2939–2954. e9.

[43] Outbreakinfo. Variant of concern reports. https://www.ecdc.europa.eu/en/news-events/epidemiological-update-omicron-data-15-december/; 2021 [accessed 15 December 2021].

[44] Luo CH, Morris CP, Sachithanandham J, Amadi A, Gaston D, Li M, et al. Infection with the SARS-CoV-2 delta variant is associated with higher infectious virus loads compared to the alpha variant in both unvaccinated and vaccinated individuals. medRxiv 2021.08.15.21260777 [Preprint]. 2021 [cited 2022 June 20]. Available from: https://www.medrxiv.org/content/10.1101/2021.08.15.21260777v1.

[45] van Kampen JJ, van de Vijver DA, Fraaij PL, Haagmans BL, Lamers MM, Okba N, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat Commun 2021;12:267.

[46] Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tukeprakhon A, et al. Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum. Cell 2021;184:4220–4236. e13.

[47] Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B. 1.617. 2 and B. 1.351 by BNT162b2 vaccination. Lancet 2021;397:2461–2.

[48] Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 2021;397:2461–2.

[49] GISAID. Tracking of Variants, https://gisaid.org/hcov19-variants/; 2022 [accessed 15 June 2022].

[50] Mykytyn AZ, Rissmann M, Kok A, Rosu ME, Schipper D, Breugem TI, et al. Omicron BA. 1 and BA. 2 are antigenically distinct SARS-CoV-2 variants. bioRxiv 2022.02.23.481644 [Preprint] 2022 [cited 2022 March 10]. Available from: https://www.biorxiv.org/content/10.1101/2022.02.23.481644v1.

[51] Garcia-Beltran WF, Denis KJS, Hoelzemer A, Lam EC, Nitidoo AD, Sheehan ML, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 2022;185:457–68.

[52] Challen R, Brooks-Pollock E, Read J, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ 2021;372:n579.

[53] Giles B, Meredith P, Robson S, Smith G, Chauhan A. The SARS-CoV-2 B. 1.1. 7 variant and increased clinical severity—the jury is out. Lancet Infect Dis 2021;21:1213–4.

[54] Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7. Nature 2021;593:266–9.

[55] Edmunds WJ, Jewell NP, Diaz-Ordaz K, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B. 1.1. 7 in England. Science 2021;372:3055.

[56] Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, et al. Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B. 1.1. 7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. Lancet Infect Dis 2021;21:1246–56.

[57] Davies NG, Jarvis C, CMMID COVID-19 Working Group, Edmunds WJ, Jewell NP, Diaz-Ordaz K, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B. 1.1. 7 in England. Science 2021;372:3055.

[58] Challen R, Brooks-Pollock E, Read J, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ 2021;372:n579.

[59] Giles B, Meredith P, Robson S, Smith G, Chauhan A. The SARS-CoV-2 B. 1.1. 7 variant and increased clinical severity—the jury is out. Lancet Infect Dis 2021;21:1213–4.

[60] Chen X, Chen Z, Azman AS, Sun R, Lu W, Zheng N, et al. Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and Pooled Analysis. Clin Infect Dis 2022;74:734–42.

[61] Collier DA, De Marco A, Ferreira IA, Meng B, Datir RP, Walls AC, et al. Sensitivity of SARS-CoV-2 B. 1.1. 7 to mRNA vaccine-elicited antibodies. Nature 2021;593:136–41.

[62] Emary KR, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial. Lancet 2021;397:1351–62.

[63] Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhashine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 2021;596:276–80.

[64] Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med 2021;27:717–26.
Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, et al. Yu J, Collier ARY, Rowe M, Mardas F, Ventura JD, Wan H, et al. Schmidt F, Muecksch F, Weisblum Y, Da Silva J, Bednarski E, Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, Mølbak UK Health Security Agency. COVID-19 vaccine surveillance. 2022;603:679

Bowen JE, Sprouse KR, Walls AC, Mazzitelli IG, Logue JK, Khan K, Møller CH, et al. Transmission of SARS-CoV-2 Omicron variant. N Engl J Med 2022;386:698–700.

Planas D, Saunders N, Maes P, Guive-Benhassine F, Flanchais C, Buchriesser J, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 2022;602:599–601.

Bowen JE, Sprouse KR, Walls AC, Mazzitelli IG, Logue JK, Franko NM, et al. Omicron BA. 1 and BA. 2 neutralizing activity elicited by a comprehensive panel of human sera against SARS-CoV-2 Omicron. Nature 2022;602:682–8.

Schmidt F, Muecksh F, Weisblum Y, Da Silva J, Bednarski E, Chao A, et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. N Engl J Med 2022;386:599–601.

Hachmann NPM, Collier AY, Ventura JD, Yu J, Rowe M, Bondzic EA, et al. Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med 2022;387:86–8.

Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature [Internet]. 2022 Jun [cited 2022 Jun 20]; [about 10 p.]. Available from: https://doi.org/10.1038/s41586-022-04980-y.

Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 2022;603:679–86.

Yu J, Collier ARY, Rowe M, Mardas F, Ventura JD, Wan H, et al. Neutralization of the SARS-CoV-2 omicron BA. 1 and BA. 2 variants. N Engl J Med 2022;386:1579–80.

Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 omicron variant neutralization in serum from vaccinated and convalescent persons. N Engl J Med 2022;386:698–700.

Carreno JM, Alashammary H, Tcheou J, Singh G, Raskin AJ, Kawabata H, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 2022;602:682–8.

Planchais C, Buchrieser J, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 2022;602:671–5.

Kawabata H, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 2022;602:682–8.

Franko NM, et al. Omicron BA. 1 and BA. 2 neutralizing activity elicited by a comprehensive panel of human vaccines. BioRxiv 2022.03.15.484542 [Preprint]. 2022 [cited 2022 Mar 20]. Available from: https://www.biorxiv.org/content/10.1101/2022.03.15.484542v1.

Heymann DL, et al. SARS-CoV-2 variants and vaccines. N Engl J Med 2021;385:1590–4.

Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 2022;602:664–70.

Cathcart AL H-DC, Lempp FA, Ma D, Schmid MA, Agostini ML, Guarino B, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. BioRxiv 2021.03.09.434607 [Preprint]. 2022 [cited 2022 Jun 12]; Available from: https://www.biorxiv.org/content/10.1101/2021.03.09.434607v1.

Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med 2021;385:e85.

Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27:1205–11.

Chemaitelly H, Tang P, Hasan MA, Wliakdoss S, Vassilis GM, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med 2021;385:e83.

Pouwels KS, Pritchard E, Matthews PC, Stossner N, Neure DW, Vitha K-D, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med 2021;27:2127–35.

Wang Z, Muecksh F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021;595:426–31.

Arbel R, Hamerman A, Sergienko R, Friger M, Peretz A, Netzer D, et al. BNT162b2 vaccine booster and mortality due to covid-19. N Engl J Med 2021;385:2413–20.

Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Altroy-Preis S, et al. Protection against Covid-19 by BNT162b2 booster across age groups. N Engl J Med 2021;385:2421–30.

Unno APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCoV-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 2021;398:25–76.

Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet 2021;385:86–9.

Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet 2021;397:2043–6.

Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, et al. SARS-CoV-2 variants and vaccines. N Engl J Med 2021;385:179–86.

Wu K, Choi A, Koch M, Eibashir S, Ma L, Lee D, et al. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Vaccine 2021;39:7394–400.